RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.

Trial Profile

RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2017

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2016 Primary endpoint has been met. (Overall (Failure: death from any cause) survival), as per an article published in the Journal of the National Cancer Institute.
    • 03 Jun 2016 Results assessing effect of institutional accrual volume on clinical outcomes published in the Journal of the National Cancer Institute
    • 19 Oct 2015 Results published in ASTRO Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top